NantHealth Inc (NH) Receives Consensus Rating of “Buy” from Analysts

Shares of NantHealth Inc (NASDAQ:NH) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $9.00.

A number of analysts have recently commented on NH shares. BidaskClub upgraded NantHealth from a “strong sell” rating to a “sell” rating in a research report on Tuesday. Zacks Investment Research cut NantHealth from a “buy” rating to a “hold” rating in a research report on Tuesday. Jefferies Group reiterated a “buy” rating and set a $5.00 target price on shares of NantHealth in a research report on Thursday, September 28th. Finally, Canaccord Genuity cut their target price on NantHealth from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, November 17th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alliancebernstein L.P. purchased a new position in shares of NantHealth during the second quarter worth about $102,000. GSA Capital Partners LLP purchased a new position in shares of NantHealth during the second quarter worth about $121,000. Teachers Advisors LLC grew its holdings in shares of NantHealth by 351.8% during the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock worth $134,000 after buying an additional 24,588 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of NantHealth by 132.4% during the second quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock worth $134,000 after buying an additional 18,000 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. purchased a new position in shares of NantHealth during the third quarter worth about $180,000. 7.10% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NantHealth (NASDAQ:NH) opened at $3.75 on Thursday. NantHealth has a 52 week low of $2.60 and a 52 week high of $10.26. The company has a quick ratio of 2.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $406.24 and a price-to-earnings ratio of -2.57.

NantHealth (NASDAQ:NH) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.01. NantHealth had a negative return on equity of 46.09% and a negative net margin of 225.76%. The company had revenue of $21.76 million for the quarter, compared to analysts’ expectations of $29.42 million. During the same period last year, the firm earned ($0.18) earnings per share. NantHealth’s quarterly revenue was up 5.3% on a year-over-year basis. equities research analysts predict that NantHealth will post -1.35 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/11/nanthealth-inc-nh-receives-consensus-rating-of-buy-from-analysts.html.

About NantHealth

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply